CHCL.BO · BSE

Cian Healthcare Limited

₹18.8

+4.97% (+₹0.89)

Prev. close

₹17.91

Volume

822

As of

18 Sept 2026

Price history

₹18.8+₹11.57 (+160.03%) · 3M
03 Nov 202518 Sept 2026
₹18.8₹4.8103 Nov01 Dec31 Dec09 Jul18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Cian Healthcare Limited in the last 90 days.

Fundamentals

About Cian Healthcare Limited

Cian Healthcare Limited engages in the research, development, manufacture, marketing, and sale of pharmaceutical products in India. It offers pharmaceutical products in various therapeutic areas of gynecology, haematinic, cardio- diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, and vitamins and nutrient products. The company also provides male and female infertility, reproductive wellness, energy boosting, autism, multivitamins, joint care products, and haematinic products, as well as face and hair serums, veterinary products, and cosmetics. It offers its products in the form of tablets, capsules, soft gels, liquid orals, ointments/ creams and sachets, and cosmetics. The company exports its products to various countries, such as Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, and Myanmar. The company was incorporated in 2003 and is based in Pune, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Ms. Kalyani Vijay Chordia C.A.

Headquarters

Pune

Employees

170

Website

cian.co

Key stats

Market cap

₹3.22 Cr

EPS (TTM)

₹-9.32

Beta (1Y · daily vs NIFTY 50)

0.42

Beta (5Y · monthly vs NIFTY 50)

-0.99

Shares float

1.21 Cr

Financial Performance

01 · Financials

-50 Cr0 Cr50 Cr100 Cr-100%-50%0%50%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

-40-20020FY22FY23FY24FY25

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-100%-50%0%50%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 Cr200 CrFY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr50 Cr100 Cr150 Cr200 CrFY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-50 Cr0 Cr50 Cr100 CrFY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹73.73 Cr₹77.87 Cr₹68.59 Cr₹61.70 Cr₹30.80 Cr₹28.30 Cr
EBITDA₹12.07 Cr₹4.79 Cr₹13.20 Cr₹11.10 Cr₹-18.98 Cr₹-18.77 Cr
₹5.30 L₹-5.53 Cr₹2.03 Cr₹84.86 L₹-25.98 Cr₹-23.29 Cr
Diluted EPS₹-32.22₹11.81₹4.96₹-10.39

Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹160.48 Cr₹161.18 Cr₹156.06 Cr₹61.55 Cr
₹60.81 Cr₹55.69 Cr₹54.99 Cr₹28.66 Cr
Stockholders' equity₹57.49 Cr₹58.33 Cr₹32.36 Cr₹8.54 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹4.84 Cr₹11.76 Cr₹20.75 Cr₹-1.47 Cr
Investing cash flow₹2.55 Cr₹-1.46 Cr₹-25.42 L₹13.27 Cr
₹-7.41 Cr₹-10.44 Cr₹-3.92 Cr₹-28.37 Cr
Capital expenditure₹-1.32 Cr₹-97.86 L₹-40.56 L₹-82.05 L
End cash position₹1.33 Cr₹1.19 Cr₹17.77 Cr₹1.20 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%
Cian Healthcare Limited₹2.65 Cr₹17.060.31-272.9%3.36-8.1%+308.1%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

No stock news captured yet.